Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | THPO | P40225 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200089 | 1.00 | ADORA3 (0.69) | ADORA3TSHRADORA2APMP22ADORA2B | |
| SCHEMBL7735031 | 1.00 | ADORA3 (0.69) | ADORA3TSHRADORA2APMP22ADORA2B | |
| SCHEMBL15144301 | 1.00 | ADORA3 (0.69) | ADORA3TSHRADORA2APMP22ADORA2B | |
| SCHEMBL5508361 | 0.99 | TSHR (0.70) | ADORA3TSHRADORA2APMP22ADORA2B | |
| SCHEMBL4649323 | 0.96 | PI4KA (0.68) | ADORA3TSHRADORA2APMP22ADORA2B | |
| SCHEMBL7733889 | 0.93 | PI4KA (0.64) | ADORA3TSHRADORA2APMP22ADORA2B | |
| SCHEMBL5507625 | 0.93 | ADORA3 (0.62) | ADORA3TSHRADORA2APMP22ADORA2B | |
| SCHEMBL15144300 | 0.91 | ADORA3 (0.60) | ADORA3TSHRADORA2APMP22ADORA2B | |
| SCHEMBL5993960 | 0.91 | ADORA3 (0.64) | ADORA3TSHRADORA2APMP22ADORA2B | |
| SCHEMBL13337622 | 0.91 | TSHR (0.69) | ADORA3TSHRADORA2APMP22ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718853-B2 | Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-YL)-3,4-dihydroxytetrahydrofuran-2-YL)] methyl nitrate and processes of preparation thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170049799-A1 | OPHTHALMIC FORMULATIONS | INOTEK PHARMACEUTICALS CORPORATION | 2017-02-23 | — | — | US | disclosed |
| US-9522160-B2 | Ophthalmic formulations | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2016-06-09 | — | — | US | disclosed |
| US-20160137686-A1 | ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)] METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF | INOTEK PHARMACEUTICALS CORPORATION | 2016-05-19 | — | — | US | disclosed |
| US-9289383-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289383-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9278991-B2 | Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150080330-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080330-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20140018314-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20130196940-A1 | ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)} METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-8476247-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-07-02 | — | — | US | disclosed |
| EP-1537133-B1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060135467-A1 | Partial and full agonists of A1 adenosine receptors | ZABLOCKI JEFF | 2006-06-22 | — | — | US | disclosed |
| US-7022681-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040043960-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-03-04 | — | — | US | disclosed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | disclosed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135467-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885TSHR 184/4885ADORA2A 2/4885 |
| US-20170049799-A1 | OPHTHALMIC FORMULATIONS | EYA3, EYA2, PDE6C | ADORA3 228/4885TSHR 1458/4885ADORA2A 314/4885 |
| US-20040043960-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885TSHR 169/4885ADORA2A 2/4885 |
| US-20160137686-A1 | ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)] METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF | NT5C3B, POR, QDPR | ADORA3 56/4885TSHR 4556/4885ADORA2A 84/4885 |
| US-20130196940-A1 | ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)} METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF | NT5C3B, POR, QDPR | ADORA3 61/4885TSHR 4534/4885ADORA2A 85/4885 |
| US-20150080330-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA3 31/4885TSHR 4172/4885ADORA2A 25/4885 |
| US-20140018314-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA3 31/4885TSHR 4172/4885ADORA2A 25/4885 |
| US-20160158268-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE3A, PDE2A, PDE6C | ADORA3 31/4885TSHR 4172/4885ADORA2A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.